Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$15.36
-3.4%		$17.03
$14.55
▼
$40.23
$1.44B0.126,167 shs8,994 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$28.27
-2.3%		$29.90
$17.00
▼
$35.83
$1.39B1.34652,550 shs507,601 shs
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
$7.55
-13.4%		$5.29
$0.18
▼
$10.99
$287.40M0.6316,333 shs8,358 shs
KARD
Kardigan
$14.79
+3.8%		$19.21
$13.75
▼
$27.00
$1.38BN/A871,935 shs524,433 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.00%+3.36%-12.86%-16.97%-61.19%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-0.63%-8.89%-18.46%+53.14%
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
0.00%-19.23%+28.62%+271.92%+830.61%
KARD
Kardigan
0.00%0.00%-28.69%-39.26%+1,478,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$15.36
-3.4%		$17.03
$14.55
▼
$40.23
$1.44B0.126,167 shs8,994 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$28.27
-2.3%		$29.90
$17.00
▼
$35.83
$1.39B1.34652,550 shs507,601 shs
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
$7.55
-13.4%		$5.29
$0.18
▼
$10.99
$287.40M0.6316,333 shs8,358 shs
KARD
Kardigan
$14.79
+3.8%		$19.21
$13.75
▼
$27.00
$1.38BN/A871,935 shs524,433 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.00%+3.36%-12.86%-16.97%-61.19%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-0.63%-8.89%-18.46%+53.14%
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
0.00%-19.23%+28.62%+271.92%+830.61%
KARD
Kardigan
0.00%0.00%-28.69%-39.26%+1,478,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.20
Buy$46.43202.27% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.70
Moderate Buy$44.8658.67% Upside
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
0.00
N/AN/AN/A
KARD
Kardigan
2.50
Moderate Buy$42.25185.67% Upside

Current Analyst Ratings Breakdown

Latest BFNH, AVBP, AAPG, and KARD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/14/2026
KARD
Kardigan
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D)
8/25/2026
KARD
Kardigan
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$51.00 ➝ $46.00
8/21/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$48.00
8/17/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $47.00
8/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$43.00 ➝ $40.00
8/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
8/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$42.00
7/17/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/15/2026
KARD
Kardigan
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/13/2026
KARD
Kardigan
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$46.00
(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$82.10M17.47N/AN/A$2.04 per share7.53
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/A($0.02) per shareN/A
KARD
Kardigan
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$177.71MN/AN/A768.00N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.62N/AN/AN/AN/A-50.26%-46.66%11/16/2026 (Estimated)
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
-$1.29M$0.01755.76N/AN/AN/A-84.67%-16.36%N/A
KARD
Kardigan
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest BFNH, AVBP, AAPG, and KARD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026H1 2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A-$0.65N/A-$0.6450N/A$22.24 million
8/12/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.9873-$1.05-$0.0627-$1.05N/AN/A
8/11/2026Q2 2026
KARD
Kardigan
N/A-$4.61N/A-$4.61N/AN/A
8/10/2026Q2 2026
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A$0.01N/A$0.01N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/AN/A
KARD
Kardigan
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
1.09
1.22
1.18
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.16
14.16
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A
25.41
25.41
KARD
Kardigan
N/A
8.72
N/A

Institutional Ownership

CompanyInstitutional Ownership
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A
KARD
Kardigan
N/A

Insider Ownership

CompanyInsider Ownership
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
39.54%
KARD
Kardigan
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
76793.40 millionN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
7749.31 million45.08 millionN/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
338.07 million23.02 millionNot Optionable
KARD
Kardigan
24193.50 millionN/AN/A

Recent News About These Companies

Kardigan, Inc. Announces Director Resignation and Appoints Kristin Reinke as New Audit Committee Chair
October 2 at 6:37 PM  |  kalkinemedia.comK
Kardigan, Inc. Announces Board and Committee Changes, Effective September 29, 2026
October 1 at 8:00 PM  |  marketscreener.comM
KARDIGAN INC, 구글 재무 부사장 라인케 이사 선임..감사위원장 맡는다
September 30, 2026  |  mk.co.krM
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
September 30, 2026  |  marketscreener.comM
Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068793
Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to Analysts
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-kardigan-inc-nasdaq-kard-stock-has-consensus-price-target-of-4225-according-to-analysts-2026-09-30/
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification
September 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945837-kardigan-stock-funded-precision-cardiology-offers-more-than-pipeline-diversification
Citadel Advisors LLC Acquires Shares of 120,000 Kardigan, Inc. $KARD
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-citadel-advisors-llc-acquires-shares-of-120000-kardigan-inc-kard-2026-09-09/
Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Rating of "Moderate Buy" from Analysts
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-kardigan-inc-nasdaq-kard-receives-consensus-rating-of-moderate-buy-from-analysts-2026-09-05/
Kardigan to Present at Two September Investor Conferences
September 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260902222995/en/kardigan-to-present-at-two-september-investor-conferences/
Kardigan’s Danicamtiv Heart Study Moves Forward, Keeping KARD on Investors’ Radar
September 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kardigans-danicamtiv-heart-study-moves-forward-keeping-kard-on-investors-radar?utm_source=marketbeat.com&utm_medium=referral
Kardigan Inc (KARD) Stock Price, Quote, News & History
August 20, 2026  |  benzinga.comhttps://www.benzinga.com/quote/kard
Kardigan: Q2 Earnings Snapshot
August 11, 2026  |  stamfordadvocate.comS
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
August 11, 2026  |  aol.comA
We've developed a first-of-its-kind medicine to battle cardiovascular disease: Kardigan CEO
June 26, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/weve-developed-a-first-of-its-kind-medicine-to-battle-cardiovascular-disease-kardigan-ceo/vi-AA26E3As
Kardigan (NASDAQ:KARD) Director Purchases $20,000,000.00 in Stock
June 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-kard-insider-buying-and-selling-2026-06-25/
How Kardigan spun deal leftovers into a $400M IPO
June 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/kardigan-spun-deal-leftovers-400m-102120124.html
Biotech stock Kardigan shows new rules of biotech investment
June 24, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/biotech-stock-kardigan-shows-new-rules-of-biotech-investment/ar-AA26nRsy
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
June 22, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260622539996/en/kardigan-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/
Kardigan Begins Process For IPO On Cardiovascular Treatments Promise
June 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4910952-kardigan-begins-process-for-ipo-on-cardiovascular-treatments-promise

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$15.36 -0.54 (-3.40%)
Closing price 10/2/2026 03:47 PM Eastern
Extended Trading
$15.07 -0.29 (-1.89%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$28.27 -0.66 (-2.28%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$28.38 +0.11 (+0.37%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

BioForce Nanosciences stock logo

BioForce Nanosciences OTCMKTS:BFNH

$7.55 -1.17 (-13.42%)
As of 10/2/2026 03:50 PM Eastern

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.

Kardigan NASDAQ:KARD

$14.79 +0.54 (+3.79%)
As of 10/2/2026 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas